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Background: This work tests the hypothesis that bladder instillation with vascular endothelial growth factor (VEGF)
modulates sensory and motor nerve plasticity, and, consequently, bladder function and visceral sensitivity.
In addition to C57BL/6J, ChAT-cre mice were used for visualization of bladder cholinergic nerves. The direct effect
of VEGF on the density of sensory nerves expressing the transient receptor potential vanilloid subfamily 1 (TRPV1)
and cholinergic nerves (ChAT) was studied one week after one or two intravesical instillations of the growth factor.
To study the effects of VEGF on bladder function, mice were intravesically instilled with VEGF and urodynamic
evaluation was assessed. VEGF-induced alteration in bladder dorsal root ganglion (DRG) neurons was performed on
retrogradly labeled urinary bladder afferents by patch-clamp recording of voltage gated Na+ currents.
Determination of VEGF-induced changes in sensitivity to abdominal mechanostimulation was performed by
application of von Frey filaments.
Results: In addition to an overwhelming increase in TRPV1 immunoreactivity, VEGF instillation resulted in an
increase in ChAT-directed expression of a fluorescent protein in several layers of the urinary bladder. Intravesical
VEGF caused a profound change in the function of the urinary bladder: acute VEGF (1 week post VEGF treatment)
reduced micturition pressure and longer treatment (2 weeks post-VEGF instillation) caused a substantial reduction
in inter-micturition interval. In addition, intravesical VEGF resulted in an up-regulation of voltage gated Na+
channels (VGSC) in bladder DRG neurons and enhanced abdominal sensitivity to mechanical stimulation.
Conclusions: For the first time, evidence is presented indicating that VEGF instillation into the mouse bladder
promotes a significant increase in peripheral nerve density together with alterations in bladder function and visceral
sensitivity. The VEGF pathway is being proposed as a key modulator of neural plasticity in the pelvis and enhanced
VEGF content may be associated with visceral hyperalgesia, abdominal discomfort, and/or pelvic pain.Background
It is highly likely that neurogenic dysfunction of the
urinary bladder is involved in various disorders of the
lower urinary tract (LUT) including neurogenic bladder,
outflow obstruction, idiopathic detrusor instability, over-
active bladder, painful bladder syndrome, and diabetic
neuropathy. In addition, chronic pathological conditions* Correspondence: ricardo-saban@ouhsc.edu
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reproduction in any medium, provided the orthat cause tissue irritation or inflammation can alter the
properties of sensory pathways, leading to a reduction in
pain threshold and/or an amplification of painful sensa-
tion (hyperalgesia) [1].
Depending on the pathology, several mediators and
their respective receptors have been proposed to
modulate peripheral nerve plasticity in the LUT, in-
cluding but not limited to: purinergic receptors in gen-
eral [2] or P2X receptor in particular [3], TRPV1 [1,4],
substance P acting on NK1 receptors [5], protease acti-
vated receptors [6], and nerve growth factor and its
receptors [7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in the pelvis is one of the suggested mechanisms under-
lying co-morbidity of pelvic disorders which is frequently
observed in the clinical setting [8]. Recently, evidence
indicated that acute colonic inflammation triggers the oc-
currence of urinary bladder detrusor instability via activa-
tion of the transient receptor potential vanilloid subfamily
1 (TRPV1) related pathways [4]. Moreover, colonic inflam-
mation-induced activation of TRPV1 receptors at the per-
ipheral sensory terminals results in an up-regulation of
voltage gated Na+ channels on the cell soma of bladder
sensory neurons [9]. This increase in channels may under-
lie the occurrence of peripheral cross-sensitization in the
pelvis and functional chronic pelvic pain [9].
The new hypothesis being tested in this manuscript is
that increased levels of VEGF observed during bladder
inflammation provoke nerve plasticity. This hypothesis
is based on evidence indicating that nerves and blood
vessels are anatomically associated, follow a common
molecular pathway during development, and their mat-
uration in adulthood may be controlled by the same key
molecules responsible for their development [10,11].
The finding that mutant mice (neurogenin1/neurogenin2
double knockout embryos) lacking sensory nerves also
show disorganized blood vessel branching [12], suggests
that local signals such as VEGF supplied by nerve
fibers, may provide a cue that determines blood vessel
patterning.
Evidence has been presented supporting the hypoth-
esis that many proteins that were originally discovered
to be required for axon guidance are implicated in the
development of the vascular [11] and lymphatic systems
[13]. But perhaps the most striking observation linking
the nervous and vascular systems is the finding that
angiogenic factors, when deregulated, contribute to vari-
ous neurological disorders, such as neurodegeneration.
The prototypic example of this cross-talk between
nerves and vessels is the vascular endothelial growth fac-
tor, VEGF [14]. Although originally described as a key
angiogenic and permeability factor, it is now well estab-
lished that VEGF also plays a crucial role in the develop-
ment of the nervous system [14].
Recently, we provided evidence that chronic inflamma-
tion increases the density of bladder sensory nerves that ex-
press: a) the transient receptor potential vanilloid subfamily
1 (TRPV1) [15], b) protein gene product (PGP9.5) [16], c)
substance P, and d) calcitonin gene-related peptide (CGRP)
[17]. We also determined that B20, a VEGF neutralizing
antibody, prevented inflammation-induced increase in sen-
sory nerves [17]. Furthermore, instillation of VEGF into the
bladder recapitulated the effect of inflammation on sensory
nerve plasticity [17], and represents direct evidence of
VEGF action on the peripheral nervous system.The scope of the present work was to determine
whether VEGF, in addition to increased sensory nerve
density, also alters the density of cholinergic nerves, and,
consequently, bladder function and visceral sensitivity.Results
Instillation of VEGF into the mouse bladder results in an
increase in sensory nerve density
It was reported that VEGF is expressed at relatively
higher amounts in nerves than in the surrounding mes-
enchymal tissue [12]. This finding led to a new appreci-
ation of the role of VEGF in neuronal development
[14,18] and stimulated us to review a possible link be-
tween VEGF-induced inflammation and bladder nerve
plasticity. To provide direct evidence that VEGF induces
bladder neuronal plasticity, VEGF was instilled into the
C57BL/6 mouse bladder. Previous results from our la-
boratory indicated that acute or chronic instillation of
VEGF into the mouse bladder caused inflammation,
characterized predominantly by the accumulation of
macrophages [17], and an increase in sensory nerve
density as indicated by image analysis of nerve fibers
positive for the nociceptive transducer vanilloid type 1
transient receptor potential receptor (TRPV1) [17]. In
the present manuscript, we expanded the time course of
VEGF exposure by including a group that received two
weekly instillations of VEGF. Female C57BL/6 mice were
instilled weekly for two weeks with VEGF (6.41 nM in
100 μl). Mice were euthanized one week after the second
VEGF instillation and the bladder was removed for image
analysis of TRPV1-positive fibers. One VEGF instillation
promotes a substantial increase in TRPV1-positive fibers
in the urothelium and lamina propria (Figure 1A) and in
the detrusor and adventitia (Figure 1B). Two VEGF
instillations resulted in the most pronounced alteration
in sensory nerve plasticity, as indicated by a peak in-
crease in TRPV1-positive fibers. After the 4th weekly
treatment with VEGF, the response was reduced. Similar
results were obtained with ChAT mice indicating that
1 and 2 weekly VEGF instillations provoked similar
increases in TRPV1 immune reactivity (data not shown).
These results provide direct evidence that VEGF partici-
pates in the plasticity of bladder sensory nerves and that
two weekly instillations of VEGF produced the largest in-
crease in sensory nerve density.A mouse model for the study of bladder
cholinergic innervation
We sought to extend our studies by investigating
whether VEGF also alters the plasticity of bladder cho-
linergic nerves. The rationale for the use of the ChAT-
cre mouse model was based on reports that staining
UROTHELIUM/LAMINA PROPRIA DETRUSOR/ADVENTITIAA B
Figure 1 Intravesical instillation of VEGF induces a time-dependent alteration in the density of TRPV1-positive sensory fibers in the
urothelium and lamina propria (A) and detrusor and and adventitia (B) layers. Quantification of TRPV1-IR in the C57BL/6 urinary bladder
isolated 1 week after: 1, 2, 4, and 6 weekly instillations of VEGF of PBS (N=8 per group). Asterisks indicate a statistically significant difference
(p values < 0.05) when compared to the PBS group.
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sizing enzyme choline acetyltransferase (ChAT) is not
consistent and often fails to detect these neurons. In
contrast, cholinergic neurons and fibers of the urinary
bladder and surrounding tissues are readily visualized in
whole mount preparations isolated from adult ChAT
mice (Figure 2A and 2B). High quality photomicro-














Figure 2 A ChAT transgenic mouse permits the visualization of cholin
in the urinary bladder, gastrointestinal tract, and uterus. Representativ
bladder removed from ChAT mice instilled with PBS (A). The pelvic ganglio
confirming previous results that intravesical instillation does not cause dam
whole mount preparations isolated from another control ChAT mouse. An
(C). In order to permit visualization of the ChAT-positive fibers in the bladd
was reduced. E is a high magnification of the area delimited by the white
small cholinergic fibers innervating the urinary bladder.positive nerves (Figure 2C, 2D, and 2E). However, using
these high quality micrographs, we found the pelvic gan-
glia to be so intensely fluorescent that the signals from
the surrounding tissues were not readily apparent
(Figure 2C, red circle). When the fluorescence of the PG
region was electronically reduced, it was possible to
image the innervation of the colon, uterus, and urinary
bladder (Figure 2D). Both preparations also allow theUterus




ergic cells and fibers in a pelvic ganglion and cholinergic fibers
e photomicrographs of whole mount preparations of the urinary
n and colon are also illustrated. (B). ChAT nerves appeared intact
age to the bladder wall. C, D, and E are confocal photomicrographs of
intense fluorescence was observed in the pelvic ganglion region
er, uterus, and colon, the intensity of the pelvic ganglion (red circle)
dotted rectangle in figure D and permits the visualization of large and
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with cholinergic nerves innervating the urinary bladder
and other pelvic organs (Figure 2B and 2C), which will
permit the capture of these cells for future patch clamp
studies. Figure 2E is a high magnification image of the
dotted square region of Figure 2D and shows the large
superficial nerve trunks innervating the adventitial coat.
As described in cross-sections presented below, these
fibers penetrate deep into the lamina propria and ramify
in the urothelium.
In order to confirm that ChAT positive fibers crossing
the urinary bladder were indeed nerve fibers, we stained
with an antibody targeting the class III β-tubulin, a
specific neuronal marker [19]. Both β-III tubulin- and
ChAT-positive fibers are distributed within the urothe-
lium and detrusor smooth muscle (Figure 3A-D). Areas
highlighted by dotted squares in Figure 3D were photo-
graphed at higher magnification to discriminate the over-










Figure 3 ChAT–positive fibers are nerve elements. Representative phot
isolated from ChAT mice. Sections were stained with DAPI (4',6-diamidino-2
antibody. A-D illustrates that both β-III tubulin- and ChAT-positive fibers ar
Areas highlighted by dotted squares in D were photographed at higher m
(red)- positive fibers fluorescence in the urothelium (E-H) and detrusor smo(Figure 3E-H) and detrusor smooth muscle (Figure 3I-L).
These images indicate substantial overlap between the
cholinergic and tubulin markers and thus show that the
cholinergic fibers are indeed neuronal.
An analysis of images from sections shows the relative
density of ChAT fluorescent fibers in the urothelium,
lamina propria (sub-urothelium), detrusor muscle, and
adventitia in comparison with areas immunostained by a
pan-neuronal marker (PGP9.5), sensory nerves (TRPV1),
and substance P containing fibers (Figure 4). It has to be
noted that PGP9.5 antibodies resulted in a non-specific
labeling of the urothelial layer. A reasonable explanation
for this artifact is that the methods recommended for
permeabilization of the tissues caused such labeling.
These findings precluded the use of the urothelium for
quantification purposes of PGP9.5 but not for TRPV1
and SP. PGP9.5 image analysis was performed in two
layers: the detrusor smooth muscle and the sub-






omicrographs of 12 μm thick cross-sections of the urinary bladder
-phenylindole) to highlight the cell nucleus and with class III β-tubulin
e distributed within the urothelium and detrusor smooth muscle.
agnification to show the overlap of beta-III tubulin(green)- and ChAT
oth muscle (I-L).
Figure 4 Relative density of ChAT-positive nerve fibers in
comparison with PGP9.5, Substance P (SP), and TRPV1. Mouse
urinary bladders were isolated from control ChAT mice and stained
for the pan neuronal marker PGP9.5, TRPV1, and SP. The density of
immunoreactive fibers was counted in 6-10 non-overlapping
cross-sectional images of the urinary bladder (400X magnification).
The number of fibers (length between 0.19-500 μm and width
0.19-2.5 μm) stained positively by a particular antibody per
cross-sectional area was calculated and the results of 6-10 fields
were averaged. This procedure was repeated for 5 bladders and the
results are expressed as mean ± SEM.
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ChAT nerves are more prominent in the detrusor
muscle when compared to TRPV1 nerves, whereas,
TRPV1 nerves are more prominent than ChAT nerves
in the lamina propria.
The finding that both sensory (TRPV1-positive) and
cholinergic nerves are involved in urinary tract disorders
such as overactive bladders [20] raises the question of
whether these two systems are anatomically distinct.
Therefore, we sought to determine whether sensory and
motor nerves are co-localized in urinary bladder. Using
bladder whole mounts that underwent blunt dissection
to separate the lamina propria from the detrusor
(Figure 5), we observed that TRPV1 and ChAT signals
appear to overlap in the lamina propria (yellow arrow on
Figure 5D) and to a lesser degree in the detrusor smooth
muscle (Figure 5H). However, high magnification photo-
micrographs (Figures 5I-L) indicate that the two types of
fibers are separate and run adjacent to each other, pri-
marily around the blood vessels (Figure 5L). Photomi-
crographs of bladder cross-sections confirm the results
obtained with whole mounts (Figure 6D). In addition,
higher magnification images illustrate the separation of
TRPV1 and ChAT fibers in intramural ganglia (Figure 6H)
as well as in the lamina propria (Figure 6L). We conclude
that the sensory and motor components do not overlap.VEGF instillation increases the number of ChAT
positive fibers
Figure 7 contains representative photomicrographs of
urinary bladders isolated from control and VEGF-treated
ChAT mice. These cross-sections suggest that VEGF
treatment resulted in an increased density of ChAT-
(Figure 7B and 7E) and TRPV1- positive fibers (Figure 7C
and 7F). For better appreciation of sensory and cholinergic
nerves, merged microphotographs were digitally amplified
and are presented on Figure 7G and 7H (note the calibra-
tion bar on Figures 7G and H and compare with the bars
on Figures 7A and D). Image analysis of nerve density
indicates that single or repeated challenge of mouse blad-
ders with VEGF resulted in a significant increase in ChAT
density in the urothelium, lamina propria, and detrusor
smooth muscle (Figure 8). Together these results indicate
that in addition to alterations of peripheral sensory
nerve plasticity (Figure 1), direct administration of
VEGF also promotes an increase in bladder cholinergic
nerve plasticity.
Urodynamic analysis of bladder function after intravesical
VEGF instillation in awake (unrestrained) mice
To evaluate the effects of intravesical VEGF on urody-
namic parameters and function of the urinary bladder
in vivo, we performed cystometric assessment in con-
scious mice. Micturition cycles were first recorded under
control conditions (N=5) and served as a baseline (in-
ternal control) followed by urodynamic evaluation at 1
and 2 weeks after beginning VEGF treatment. Figure 9
shows raw cystometric traces recorded in the same animal
before (Figure 9A, baseline) and 2 weeks after intravesical
VEGF (Figure 9B). Urodynamic parameters were first
compared to the baseline for each mouse followed by fur-
ther comparisons between the groups (before and after
treatment). Intravesical VEGF caused significant changes
in the function of the urinary bladder over the course of
treatment (Figure 9B).
At 1 week post-VEGF, significant changes included a
reduction in micturition pressure (19.75 ± 0.53 mmHg
at baseline vs 14.4 ± 0.32 mmHg at 1 week, (Figure 10B,
p≤0.005) and decreased micturition volume (by 26% in
comparison to baseline, (p≤0.001, Figure 10C). These para-
meters were also significantly reduced 2 weeks after the
initiation of VEGF treatment. Longer treatment (2 weeks)
caused a substantial reduction in inter-micturition interval
from 341.2 ± 25.6 s to 188.0 ± 20.8 s (p≤0.001, Figure 10A)
and a decrease in bladder capacity from 57.1 ± 4.3 μl to
31.6 ± 3.5 μl (p≤0.001, Figure 10D). There was a tendency
towards an increase in the number of non-micturition
contractions (pointed by arrows in Figure 9B) after intra-
vesical VEGF, although the difference did not reach sta-
tistical significance (Figure 10E). Other cystometric
parameters such as intermicturition pressure interval,
100 μm
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Figure 5 Representative photomicrographs of bladder whole mounts showing ChAT-positive nerve fibers, sensory nerves (TRPV1), and
blood vessels (CD31). Representative photomicrographs taken from bladders isolated from ChAT mice and prepared as whole mounts that
underwent blunt dissection to separate the lamina propria from the detrusor. In the lamina propria (D) the ChAT and TRPV1 fibers are usually
associated (yellow arrow) but sometimes take separate paths (red and green arrows). In the detrusor (H) ChAt-positive fibers dominate although
the ChAT and TRPV1 fibers around blood vessels are usually associated (yellow arrow). High magnification microphotographs (I-L) indicate that
the two type of fibers run adjacent to each other (L).
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VEGF treatment. Additional group of mice (N=5) under-
went intravesical instillations with PBS and cystometric
parameters were recorded at the same time points as in
the VEGF group. Intravesical PBS did not significantly
affect the function of the urinary bladder (Figure 10A-E).
In addition, the baseline values did not differed between
the PBS and VEGF groups and, therefore, baseline values
were combined in Figure 10.Intravesical VEGF caused an up-regulation of voltage
gated Na+ channels (VGSC) in bladder DRG neurons
It is well established that bladder inflammation causes
an increase in VGSC expressed in sensory neurons re-
ceiving input from the urinary bladder [21]. In this set of
experiments we aimed to determine if intravesical VEGFwould cause any changes in VGSC, thereby, affecting
neuronal excitability of bladder projecting afferents.
Retrograde labeling of lumbosacral sensory neurons
with Fast Blue allowed identification of bladder project-
ing DRG cells used for electrophysiological recordings
and data analysis. Bladder inflammation caused by intra-
vesical VEGF triggered an increase in the amplitude of
total Na+ current recorded from bladder afferent neu-
rons. Representative raw recordings of total Na+ current
obtained from the control (intravesical PBS) and experi-
mental (intravesical VEGF) groups are presented in
Figure 11A. The current–voltage (I-V) relationship of total
Na+ current normalized to the cell size shows that these
neurons produced a large amplitude Na+ current upon
membrane depolarization, reaching maximal amplitude at
-20 mV (Figure 11B). VEGF application increased the
peak amplitude of total Na+ current in bladder DRG
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Figure 6 Photomicrographs of bladder cross-sections confirm the results obtained with whole mounts and indicate the predominance
of TRPV1 fibers in the urothelium and the predominance of ChAT fibers in the detrusor smooth muscle. A-D are representative
photomicrographs of the entire bladder cross section. E-H are representative photomicrographs of the detrusor smooth muscle taken at high
magnification to show some areas of overlap between ChAT and TRPV1, primarily in intramural fascicles (H). I- L are representative
photomicrographs of bladder urothelium taken at high magnification to show some areas of overlap between ChAT and TRPV1, primarily in the
lamina propria (sub urothelium), as illustrate (L).
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control group to -253.5 ± 43.5 pA/pF (n=9) in the VEGF
group (p≤0.05). Significant enhancement of total Na+
current was observed at all voltages from -30 mV to +20
mV (Figure 11B).
We next assessed the kinetic parameters of total Na+
currents after the induction of neurogenic bladder in-
flammation caused by VEGF. The steady-state activation
was studied by using a three-pulse protocol with a nega-
tive pre-pulse to -110 mV and a series of short depolar-
izing pulses (10 ms duration) to activate Na+ currents
(Figure 12A, top panel). The amplitude of steady-state
activation was measured at the peak of tail current upon
the voltage step to -70 mV, normalized and plotted as
I/Imax against the voltage (Figure 12A, lower panel).
Intravesical VEGF led to the leftward shift in the steady-
state activation of total Na+ current by 8 mV (V1/2=-19.9± 2.6 mV in the control group vs -27.6± 2.0 mV at 2
weeks of treatment, Figure 12B, p≤0.05). The amplitude of
steady-state inactivation was measured at a series of mem-
brane depolarizing steps ranging from -100 mV to +70
mV (Figure 12C). Bladder inflammation did not affect
the parameters of steady-state inactivation of total Na+
current in bladder sensory neurons (Figure 12D).
VEGF triggered an enhanced abdominal sensitivity to
mechanical stimulation with von Frey filaments
Abdominal sensitivity was tested in a separate group of
mice (N=7) before and after bladder treatments with
VEGF. Figure 13 summarizes the frequency of responses
to von Frey filament testing in the lower abdominal area
before, and 1 week and 2 weeks after intravesical instilla-
tions of VEGF in the same group of mice. The response






















Figure 7 Representative photomicrographs of ChAT mouse bladder cross-sections isolated from control and a single VEGF instillation
(Table 1). Flattened images from 10 μm thick cross-sections from control and VEGF treated are presented side by side to permit comparison.
DAPI staining highlighted the cell nuclei (A and D), ChAT was visualized by the fluorescent protein (td tomato; B and E), and sensory nerves were
identified by TRPV1 immunoreactivity (C and F). Enlarged and merged microphotographs are presented to permit a better appreciation of the
differences between control (G) and VEGF-treated bladders (H).
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(Figure 13). One week after VEGF treatment, mice be-
came more sensitive to the filament testing and responses
reached more than 40% at lower forces of 0.16 g and 0.4 g
(Figure 13, p≤0.05 to baseline). Two weeks after the treat-
ment the frequency response showed significant differ-
ences with stimuli of 1 and 4 g filaments in comparison to
1 week (Figure 13, p≤0.05 to baseline).
These results provide evidence that intravesical VEGF
leads to an increased viscerosomatic response to cutane-
ous stimulation in the pelvic region. Such a response is
usually associated with abdominal discomfort and/or
pelvic pain.
Discussion
The major findings of the present manuscript are: 1)
the instillation of VEGF produces an increase in sensory
nerve density, presumably by nerve sprouting, that reachesa maximum at 2 weeks and declines by 4 weeks; 2) in
addition to significant increase in sensory nerve fibers,
VEGF increases the density of bladder cholinergic nerve
fibers; and 3) the increase in nerve density produced by
VEGF results in altered bladder function and visceral sensi-
tivity. The unique feature of our findings is that VEGF pro-
duces an increase in nerve density via urothelium.
The nervous and vascular systems share several ana-
tomical parallels. Both systems utilize a complex branch-
ing network of neuronal cells or blood vessels reaching
all regions of the body. The anatomical similarity of the
nervous and vascular systems suggests that axons might
guide blood vessels and vice-versa [22]. Indeed, signal
molecules produced by peripheral neuronal cells, such
as VEGF [12], guide blood vessels [14] and signals from
vessels, such as the neurotrophins NGF and NT-3, are
required for, and orchestrate extension of neurons adja-
cent to vessels [23]. In this manner, the neuronal and
LAMINA PROPRIA DETRUSORUROTHELIUMA B C
Figure 8 VEGF increases the density of cholinergic nerves. ChAT-positive fiber density in the urinary bladder isolated from ChAT mice 1 week
after treatment with PBS, or 1 and 2 weeks of after VEGF instillations. The results indicate a significant increase in ChAT density in the urothelium
(A), lamina propria (B), and detrusor smooth muscle (C). The density of immunoreactive fibers was counted in 6-10 non-overlapping
cross-sectional images of the urinary bladder (400X magnification). The number of fibers (length between 0.19-500 μm and width 0.19-2.5 μm)
stained positively by a particular antibody per cross-sectional area was calculated and the results of 6-10 fields were averaged. This procedure
was repeated for all bladders and the results are expressed as mean ± SEM. (N=5 per group).
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http://www.biomedcentral.com/1472-6793/12/15vascular systems are well organized and coordinated in
normal adult tissues. However, in chronic inflammatory
states particularly in the LUT, little is known about how
the nerve-vessel relationship functions and whether it


























Figure 9 Representative cystograms recorded in awake and freely mo
mice before (A = baseline) and after (B = lower panel) intravesical VEGF in
non-micturition contractions were observed in all mice from the VEGF grou
BP- Bladder pressure, BC – bladder capacity, MV – micturition volume.patients with disorders of the lower urinary tract. In this
context, this manuscript presents a body of evidence im-
plicating VEGF signaling in the enhanced innervation of
the urinary bladders in mice and the consequent alter-
ation in mechanical responses and visceral sensitivity.4 min
ving mice. Top panel shows raw traces recorded in one of the
stillations. An increase in voiding frequency and the number of










Figure 10 Analysis of urodynamic parameters recorded in conscious and unrestrained mice. Comparison of the intermicturition interval
(A), pressure at micturition (B), micturition volume (C), bladder capacity (D) and number of non-voiding contractions (E) in mice before, after 1































Figure 11 The amplitude of voltage-gated Na+ currents is increased in bladder sensory neurons isolated from VEGF-treated mice.
A, Top panel presents the scheme of voltage protocol for recordings of voltage gated Na+ currents including depolarizing pulses from -70 mV to
+60 mV ( 10 mV increments) from the holding potential of -70 mV. Lower panel shows representative raw traces recorded from VEGF group 2
weeks after the beginning of the treatment. B, Current-voltage (I-V) relationship of the total Na+ current recorded in bladder DRG neurons after
intravesical application of VEGF (2 weeks). * - p≤0.05 when compared to control group.
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Figure 12 Kinetics of voltage gated Na+ channels recorded in bladder DRG neurons. A: The protocol (top panel) of steady-state activation
and raw traces (bottom panel) of total Na+ current. The steady-state activation of VGSC was assessed by using a three-pulse protocol with a
negative pre-pulse to -110 mV and a series of short pulses of 10 ms duration from -110 mV to +70 mV to activate Na+ currents. B: Voltage
dependence of steady-state activation in bladder neurons from control and VEGF treated animals. Please note a leftward shift in the group with
VEGF instillations suggestive of channel opening at more negative potentials. C: The protocol of steady-state inactivation (top panel) and raw
traces of the recorded Na+ current (bottom panel). The amplitude of steady-state inactivation was measured at 0 mV after 150 ms depolarizing
pulses ranging from -100 mV to 70 mV. D: Voltage dependence of steady-state inactivation of Na+ channels in lumbosacral bladder DRG neurons
was not different in the control group and VEGF-treated mice.
Malykhina et al. BMC Physiology 2012, 12:15 Page 11 of 21
http://www.biomedcentral.com/1472-6793/12/15Interest in guidance molecules, and particularly VEGF,
modulating both vascular and neuronal pathology is
emerging [14]. Changes in VEGF levels are associated
with alterations in the vascular system of the urinary
bladder [17]. VEGF is increased in bladders of patients
with painful bladder syndrome, and this increase is asso-
ciated with glomerulations on hydrodistension [24].
However, increased bladder VEGF is not observed in
patients who do not show petechial bleeding or in con-
trols [24], suggesting that VEGF levels are associatedwith those PBS patients exhibiting alterations in the
bladder microvascular system.
At this moment, it is not readily apparent which of the
VEGF receptor subtypes mediates the bladder neuro-
plasticity in the mouse model. Both VEGFR1 and
VEGFR2 as well as NRP1 and NRP2 are highly
expressed in urothelium and intramural ganglia [25]. We
also reported that control human bladders urothelium
present a predominance of VEGFR1 and NRP2 over
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Figure 13 VEGF triggered an enhanced abdominal sensitivity in
response to mechanical stimulation with von Frey filaments.
Effects of intravesical VEGF on the development of viscerosomatic
hyperalgesia as measured by the response to mechanical
stimulation of the lower abdominal area using von Frey
filaments. * - p≤0.05 when compared to the control group. This data
suggests that intravesical VEGF induced the development of
abdominal hypersensitivity in pelvic area which could be a reflection
of abdominal discomfort/pain.
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pression [26]. Nevertheless, our results strongly suggest
a new and blossoming VEGF-driven processes in the
bladder that may be a putative target in neuronal plasti-
city. However, the role of VEGF pathway in bladder neu-
roplasticity is in its infancy. In contrast, the roles of
NGF and BNDF in neuroplasticity are well established in
bladder pathology (e.g., due to spinal cord injury) and
have resulted in the testing of NGF-/BNDF-antibodies
(or siRNA knockdown) as possible therapeutic options.
Therefore, it is tempting to propose that VEGF neutral-
izing antibodies, such as avastin, or VEGF receptor
antagonists may be of benefit to reduce inflammation-
induced bladder neuronal plasticity. However, it has to
be kept in mind that this growth factor is necessary not
only for developing vessels and angiogenesis but also
VEGF signaling is required for vascular homeostasis [27]
and the consequences of reduced levels of VEGF can im-
pact the kidney vasculature as seen in pre- eclampsia
[28]. A promising alternative for neutralization of VEGF
seems to be the blockade of neuropilins by engineered
antibodies [29]. However, it is too early to predict
whether neutralization of neuropilins will have any dele-
terious effect on the established vasculature.
The rationale for the methodology employed here is
based upon our previous observations that VEGF is
taken up by the intact urothelium. We showed that fol-
lowing intravesical instillation of a fluorescent VEGF
tracer (scVEGF/Cy5.5 ) which only internalizes in cells
expressing active VEGF receptors [30], results in accu-
mulation of this growth factor in suburothelial layers[31,32]. After binding these receptors, VEGF may be
transcytosed by the urothelial cells into deeper subur-
othelial layers. Alternatively, VEGF could affect the per-
meability of the urothelium through mechanisms
reminiscent of VEGF’s effects on vascular permeability,
which results in paracellular transport of VEGF. Indeed,
the protein constituents comprising this highly effective
urothelial barrier (tight junctions), occludins [33], clau-
dins [34], and zonula occludens-1 [35] have been re-
cently studied in detail [36] and are known targets of
VEGF-mediated effects on vascular permeability. After
the uptake, VEGF produces both bladder inflammation
and changes in neuronal plasticity [17]. The hypothesis
that VEGF is taken up by the urothelium was substan-
tiated by the following findings: 1- VEGF receptors are
expressed in the mouse [32] and human bladders [31];
2-VEGF neutralizing antibodies significantly reduced
inflammation and neuronal plasticity induced by intrave-
sical Bacillus Calmette-Guérin (BCG) stimulation [17];
3- An antibody targeting neuropilins (VEGF co-receptors)
reduces bladder inflammation [37]; 4- VEGF itself repro-
duced the findings obtained with BCG by causing bladder
inflammation and sensory nerve plasticity [17].
Increase in cholinergic fibers
Although an increase in sensory nerve density, particu-
larly those expressing TRPV1-IR, has been proposed to
underlie pain sensation and neurogenic detrusor over-
activity [38], our past work did not explore whether the
increased nerve density also resulted in altered function
[17]. In order to investigate motor nerves, we used a
unique mouse model expressing a fluorescent protein
under the endogenous Chat gene promoter, we present
evidence that direct application of VEGF into the mouse
bladder increases the density of peripheral cholinergic
nerves. To the best of our knowledge this increase in
cholinergic nerve fibers represents a new finding
that was only possible by the use this ChAT transgenic
mouse, a model which will open a new area of re-
search on the role of VEGF and its receptors in blad-
der motor function.
How does VEGF produce its effects?
VEGF and its receptors are known neuronal guidance
molecules and, therefore, it is expected that they affect
nerves. However, the inflammation induced by VEGF
may be another possible mechanism leading to an in-
crease in neuronal density. Indeed, VEGF mediates in-
flammation in the bladder as shown by the findings that
instillation of VEGF causes vasodilation, edema, and
macrophage recruitment, hallmarks of inflammation
[17], while application of neutralizing VEGF antibodies
significantly reduce bladder inflammation [37]. At this
time, there is no definitive evidence suggesting a specific
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However, given the known trophic effects of VEGF on
neurite growth prolonged survival of neurons [39,40],
and reinnervation following local nerve damage [41,42],
it is reasonable to propose that inflammatory cells pro-
ducing VEGF may mediate these growth effects on neu-
rons. This new appreciation of VEGF signaling in
bladder inflammation is supported by emerging evidence
that VEGF is increased at the site of inflammation, and
that infiltrating lymphocytes and other inflammatory
cells may represent additional sources of VEGF [43].
The involvement of cholinergic nerves on bladder in-
flammatory responses to VEGF suggests a cross-talk be-
tween the autonomic and immune systems. Whether the
immune system is functionally and anatomically con-
nected to the bladder nervous system remains to be
determined. However, a recent investigation proposes
that afferent and efferent signals transmitted in the
vagus nerve modulate innate immune responses and are
components of an inflammatory reflex [44,45]. There-
fore, it is fair to propose that VEGF increases the cross-
talk between the immune and autonomic systems.
VEGF alters bladder function
We showed for the first time that VEGF affects bladder
function and modulates micturition reflex pathways.
Analysis of urodynamic parameters recorded in con-
scious mice confirmed the suggested role of VEGF in
modulation of micturition reflex pathways. It is known
that exogenous VEGF (or hypoxia induced upregulation
of the growth factor) can lead to detrusor and urothelial
hypertrophy and hyperplasia [46]. In addition, previous
immunohistochemical analyses of human specimens
detected increased innervation in the suburothelial and
detrusor layers of the urinary bladder in PBS patients
[47,48]. In our mouse model, we established that intrave-
sical VEGF treatment resulted in an increase in the dens-
ity of ChAT fibers in both the detrusor smooth muscle
and urothelial layers. This increase in nerve density was
associated with altered bladder function as indicated by a
decrease in the duration of intermicturition interval,
reduced voiding pressure, micturition volume and blad-
der capacity during continuous filling cystometry. At this
time, the individual contributions of sensory and motor
nerves to the VEGF-induced increased bladder motility
are not clear. Blockade of TRPV1 with capsazepine may
shed some light in this respect.
Our results are consistent with other studies which
established similar urodynamic changes in animal models
of bladder irritation/inflammation [49-51]. For instance,
overexpression of neurotrophic nerve growth factor
(NGF), a well-known modulator of neural plasticity, in
the urinary bladder of mice caused bladder hyperreflexia
associated with increased voiding frequency [7,52]. Thesechanges were accompanied by an increased density of
calcitonin gene-related peptide, SP and neurofilament
(NF) 100 positive fibers, as well as tyrosine hydroxylase-
positive sympathetic nerve fibers within the suburothelial
nerve plexus of the urinary bladder [7]. Additionally, ex-
pression of several TRP channels, including TRPA1,
TRPV1, and TRPV4, was increased in the urinary blad-
der of mice over-expressing NGF [53]. Interestingly,
the urinary bladder phenotype observed in mice with
urothelial overexpression of NGF was associated pre-
dominantly with the afferent limb of the micturition re-
flex, whereas our results provide evidence that VEGF
affects both afferent and efferent neural pathways. Our
data confirmed the suggestion that VEGF may be a po-
tent modulator of neural plasticity in the LUT. Other
investigators also suggested that VEGF is a more potent
stimulator of neuronal plasticity compared to a number
of different neurothrophic factors [54-56]. However, a
cross-talk between VEGF and neurotrophins cannot be
discarded. On one hand administration of VEGF can
support and enhance the growth of regenerating nerve
fibers, probably through a combination of angiogenic,
neurotrophic, and neuroprotective effects [57] and con-
versely, neurotrophins, such as NGF have been described
as pro-angiogenic factors [58]. On the other hand VEGF
had neurotrophic effects comparable with BDNF, NT3,
or NT4 on the rat isolated pelvic ganglia in culture, [54].
In addition, VEGF was found to be more potent than
BDNF in inducing ChAT-expressing fibers [54,55].
Moreover, the synergistic biological activity of VEGF and
NGF [59] is supported by the finding that mechanical
stretch of sympathetic neurons seems to induce VEGF
expression via a NGF and CNTF signaling pathway [60].
An intriguing recent hypothesis explaining the cross-talk
between VEGF and neurotrophins proposes the conver-
gence of putative signaling downstream of receptor tyro-
sine kinases [61]. In this work, Kidins220 /ARMS
(Ankyrin repeat-rich membrane spanning) was identified
as a main player in the modulation of neurotrophin
and VEGF signaling in vivo, and a primary determinant
for neuronal and cardiovascular development [61]. In
support of this hypothesis, it was demonstrated that
Kidins220 interacts with neurotrophin, VEGF, ephrin,
and glutamate receptors, and is a common downstream
target of several trophic stimuli [61,62]. Adding to the
cross-talk between neurotrophins and VEGF on neuronal
plasticity, the present results go one step further by indi-
cating that VEGF alters both sensory (TRPV1) as well as
motor (ChAT) nerves. Our present results suggest the
idea that across-talk between VEGF and neurothropins
controls bladder motor (ChAT) nerve plasticity.
Electrophysiological recordings in vitro and in vivo
revealed several distinct classes of afferent fibers that
participate in transmission of sensory signaling upon
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ical irritation and inflammation [63]. Sensory neurons
located within DRG are the first cells to receive afferent
input from the pelvic viscera and, therefore, play a sub-
stantial role in the development of visceral sensitivity
and pelvic discomfort during pathophysiological con-
ditions. DRG neurons express several types of ion
channels including TRPV1 and voltage-gated sodium
channels (VGSC), both of which are well known trans-
ducers of nociceptive processing in pain pathways
[64,65]. Experiments utilizing animal models of acute
and chronic inflammation in the genitourinary tract
showed an increased excitability of DRG neurons receiv-
ing direct input from the affected organs [49,66,67]. In
this study, we determined that instillations of intravesical
VEGF caused an up-regulation of VGSC in bladder sen-
sory neurons identified by retrograde labeling. Overex-
pression of VGSC in bladder DRG cells is associated with
increased neuronal excitability and enhanced firing rate
[21]. Our results also support the data from human stud-
ies which suggested that abdominal pain and altered blad-
der and pelvic hypersensitivity in patients with OAB and
PBS may involve organizational and/or functional changes
in visceral afferent pathways when bladder sensory neu-
rons become sensitized and hyper-responsive to normally
innocuous stimuli such as bladder filling [68,69].
Multiple sodium channel isoforms are expressed in DRG
neurons [70]. Sodium channels play a central role in neur-
onal electrogenesis, therefore, variations in the level of ex-
pression of any one of the sodium channel isoforms could,
in principle, alter their level of excitability [71]. However, a
number of modulatory factors such as neuronal functional
status, homeostatic regulation of ion channel expression,
post-translational modifications, and interactions with regu-
lating molecules and trophic factors can also significantly
affect neuronal excitability [70]. For instance, brief exposure
to NGF, interferon gamma, epidermal growth factor or
basic fibroblast growth factor can induce an up-regulation
of expression of NaV1.7 channel [72]. Interactions of Na
+
channels with partner molecules including NGF [73,74],
GDNF [73], contactin [75,76], annexin [77], gabapentin
[78], and other modulators [79] were established to regulate
expression of multiple sodium channel isoforms. Based on
these observations, we suggest that the effects of VEGF
treatment on Na+ channels in our study could be associated
either with the changes in the expression ratio between dif-
ferent Na+ channel isoforms in bladder sensory neurons or
modulation of Na+ channel function by regulatory mole-
cules as outlined above [70]. Additional studies are war-
ranted to identify the exact mechanisms of VEGF action on
specific Na+ channels isoforms and electrical activity of
bladder sensory neurons.
The results of behavioral experiments revealed, for the
first time, that intravesical VEGF induced the developmentof abdominal hypersensitivity detected by mechanical
stimulation of the lower pelvic region. These effects may be
explained, in part, by the ability of VEGF to increase the
density of SP and TRPV1 positive fibers [17]. This sugges-
tion correlates with the previously published studies, which
confirmed participation of TRPV1 in the development of
abdominal hyperalgesia and neuropathic pain [80]. Results
with TRPV1 knockout mice support the role of TRPV1 in
mediating changes in sensitivity. Wang et al. determined
that abdominal hyperreactivity and cutaneous allodynia
were significantly diminished in these genetically modified
animals although the lack of functional TRPV1 receptors
did not improve the histological changes in the inflamed
bladder induced by either cyclophosphamide (CYP) or
acrolein [51]. In addition to the involvement of TRPV1
afferents in pelvic sensitivity, other receptors and mole-
cules can also contribute to abdominal hyperalgesia de-
pending on the model and nature of chosen inflammatory
agents [81]. Thus, increased peripheral sensitivity in mice
with bacterial cystitis was related to activation of toll-like
receptor 4 [82]. In the acrolein model of bladder inflam-
mation in rats, increased mechanical sensitivity was con-
veyed, in part, via NGF and trk receptors [83]. Likewise,
inflammatory events experienced earlier in life were estab-
lished to trigger long lasting changes in sensory pathways
leading to altered pelvic sensations during the adulthood
[84,85]. Altogether, our data provide direct evidence that
VEGF-induced neurogenic inflammation in the urinary
bladder is associated with significant structural and func-
tional changes that may play a key role in the development
of neurogenic bladder dysfunctions in humans.Conclusion
The discovery that neuronal guidance molecules such as
neuropilins function as co-receptors for VEGF has
opened up a new field of VEGF research and has even
revealed potentially new roles for VEGF in axonal
growth [86]. In other words, sprouting of neuronal
axons and vessels appear to use common molecular
mechanisms for navigation based upon NRP-VEGF
interactions [87].
We previously provided strong evidence indicating that
the mouse [25] and human urothelium [31] express an
extraordinary level of VEGF receptors and that the expres-
sion of these receptors is fundamentally altered in bladder
biopsies of PBS patients [31]. Additional results supported
the hypothesis that the mouse bladder urothelium actively
internalizes VEGF [31].
Nevertheless, the function exerted by VEGF in the LUT
is not clear. In both neuronal and vascular cells VEGF is
known to increase permeability, prevent apoptosis [88],
and promote cell survival [89] and proliferation [90].
Whether VEGF exhibits the same functions on urothelial
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this manuscript indicate that VEGF also participates in
bladder neuronal plasticity and that the increased nerve
density is accompanied by alterations in bladder function
and visceral sensitivity.Methods
Animals and experimental groups
All animal experimentation conformed to the APS’s Guid-
ing Principles in the Care and Use of Animals and was
approved by the OUHSC Animal Care & Use Committee
(protocol #08-105), University of Wisconsin-Madison
(protocol M02497), and University of Pennsylvania School
of Medicine (protocol # 802979)
For the visualization of cholinergic neurons we used
genetically engineered mice with an "IRES-Cre" sequence
inserted downstream of the stop codon such that cre
expression is controlled by the endogenous Chat gene
promoter (B6;129S6-Chattm1(cre)Lowl/J.; Jackson Labora-
tories stock # 006410). We mated the ChAT-cre mice
with Rosa stop td tomato mice. The resulting offspring
express the fluorescent protein (td tomato) in all cholin-
ergic cells and fibers, as the cre deletes the stop signals
flanking the td tomato sequence. In these mice, Chat
gene expression, however, is unaffected. For simplicity,
this mouse strain will be referred as ChAT mice.
Adult C57BL/6J and ChAT female mice (10-12 wks old,
Jackson Laboratory) were used in this study and main-
tained on a 12-hour light/dark cycle with ad libitum ac-
cess to water and food.
Intravesical instillation was described in [91]. Briefly,
2-4 month-old female mice were anesthetized with iso-
flurane (between 1 and 2.5% titrated to effect) and trans-
urethrally catheterized with a polypropylene catheter (24
gauge; ¾ in.; 19 mm long, inside diameter 0.47 mm, out-
side diameter 0.67 mm; Angiocath, Becton-Dickinson,
Sandy, UT). Test compounds were instilled via a syringe
attached to the catheter at a slow rate to avoid trauma and
vesicoureteral reflux. 100 μl of one of the following sub-
stances were instilled: pyrogen-free saline (PBS; controls)
or mouse recombinant VEGF, also known as VEGF-A or
VEGF165 (6.41 nM in 100 μl; ProSpec-Tany TechnoGene
Ltd [Rehovot 76124, Israel; catalog # MGC70609]). To en-
sure consistent contact of substances with the bladder and
to avoid reflux or leakage, the catheter was occluded and
left in place for 30 minutes. Mice received one or twice
weekly innstillation of VEGF, as described in the particular
figure legend. The groups of mice were euthanized one
week post-instillation, and the urinary bladders were
removed and examined as whole mounts. Subsequently,
the urinary bladders were sectioned and visualized as
cross-sections and immunofluorescence was used for
image analysis of cholinergic and sensory nerves.Functional Studies
C57BL/6J female mice were randomly divided into three
experimental groups: 1 – cystometry studies (N=5); 2 -
control group for electrophysiological experiments (intra-
vesical PBS, N=5); 3 – VEGF group (intravesical VEGF,
N=5). Animals in all groups first underwent survival sur-
geries as described below followed by 3 intravesical instil-
lations of either PBS or vascular endothelial growth factor
(VEGF, 100 μL, 6.41 nM in 100 μl, groups 1 and 3) within
a 2-week period (every 4th day), see Table 1.
Bladder whole mounts
Urinary bladders were isolated from ChAT mice, the
urine was drained, and tissues were fixed in 4% parafor-
maldehyde for 4-6 hours at room temperature or over-
night at 4°C. After fixation, the tissue was washed in PBS
twice and placed in 1% triton X-100 for 4-6 hours at room
temperature or overnight at 4°C. After the tissue was
washed in PBS, the primary antibodies were added for 4-6
hours at room temperature or overnight at 4°C, washed
off in PBS, and the secondary antibodies were added for
4-6 hours at room temperature or overnight at 4°C.
Whole mounts were visualized and photographed with a
dissecting fluorescence microscope (Nikon SMZ 1500
microscope equipped with high-resolution Plan 1.6 WD24
objective lenses). For detailed visualization of ChAT and
TRPV1 nerves along with blood vessels, some of the
whole mounts were blunt dissected to separate the
urothelium together with the suburothelium/lamina pro-
pria [92] from the detrusor smooth muscle. Photomicro-
graphs were taken with the lamina propria facing upward
and the urothelium downward or the detrusor smooth
muscle facing upward and the adventitia downward. Sub-
sequently, tissues were frozen in 1:1 tissue freezing media
(TFM, Triangle Biomed Sciences) and OCT (Tissue TekW)
and sectioned with a cryostat. Cross-sections were exam-
ined by immunofluorescence, as described below.
Immunofluorescence (IF) of mouse tissues
Urinary bladders were processed for IF according to pub-
lished methods [93]. For all tissues, appropriate cross-
sectional morphology was confirmed by H&E staining and
examination by light microscopy prior to preparing slides
for IF labeling. Frozen sections (10, 15, or 40 μm thick, as
indicated in the figure legend) were post-fixed in 1%
MeOH-free formaldehyde for all stains. Briefly, slides were
blocked for 35 minutes with 5% normal donkey serum
(NDS; Jackson Immunolabs), then co-incubated with pri-
mary antibodies in 0.5% NDS for 90 minutes in a humidi-
fied chamber or overnight at 4°C. When double IF was
used, following brief rinses with PBS, slides were co-
incubated with both secondary antibodies at the same
time. Controls included slides labeled only with individual
primary or secondary antibodies.
Table 1 Experimental scheme for functional studies
DAYS 0 1 5 7 9 14
PROCEDURES
1st instillation of VEGF 2nd instillation of VEGF 3rd instillation of VEGF
Cystometry (Baseline) Cystometry (1 week) Cystometry
(2 weeks)
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TRPV1 antibody (1:10,000) was raised in rabbits against
the 15 C-terminal amino acids of the rat TRPV1 se-
quence [94]. Commercially available antibodies included:
rabbit anti-human protein gene product 9.5 [PGP9.5]
(Neuromics; catalog # RB12103, 1:1500 dilution), rabbit
anti-mouse substance P (Millipore; catalog AB1566;
1:250 dilution), guinea pig anti-rat substance P (Milli-
pore; catalog AB15810; 1:1000 dilution), rat anti-mouse-
derived endothelioma cell line [CD31] (BD Pharmingen;
#550274; 1:200), rabbit anti-β III tubulin [TuJ1] (Gift
from Dr. Anthony Frankfurter; 1:250).
Secondary antibodies
All secondary antibodies were used at a 1:500 dilution
and included donkey anti-rabbit IgG Alexafluor 488 and
546 conjugate (Molecular Probes), donkey anti-goat IgG
Alexafluor 546, donkey anti-rat IgG Alexafluor 488, goat
anti-guinea pig 546 ,donkey anti-rat Cy5 (Jackson
ImmunoResearch), donkey anti-rabbit Dylight 488),
donkey anti-rabbit Cy5. Slides were washed, counter-
stained with 4’, 6-diamidino-2-phenylindole (DAPI), and
coverslipped.
Image analysis
A Nikon A1R scanning confocal microscope (Melville,
NY) controlled by NIS-Elements C (Nikon) was used to
image whole mounts and cross sections at UW-Madison.
For image analysis, all tissue cross-sections were viewed
with a Nikon Eclipse TE 2000-S inverted fluorescent
microscope at OUHSC and imaged at room temperature
using a digital CCD camera (Roper Scientific; Sarasota,
Florida 34240) driven by NIS-Elements AR 3.0 Imaging
software. A control slide stained only with secondary anti-
body was used to determine exposure time and to set
minimum background fluorescence levels for each fluoro-
phore imaged. Once set, exposure times were not changed
during acquisition of each respective fluorophore in the
staining series. Staining was considered positive only when
the acquired signal exceeded the established background.
Absence of signal bleed-through was determined using
previously optimized multi-acquisition settings on singlefluorophore stained slides. DAPI staining was viewed using
a DAPI filter set (340-380nm ex, 435-485nm em). Imaging
of Alexafluor 488 utilized an excitation filter of 465-495nm
and an emission filter of 515-555nm. Alexafluor 546 was
imaged with an excitation of 528-553nm and 590-650nm
emission range.
Quantification of nerve fibers
Histologically nerve fibers undulate in and out of the
plane of the section, sometimes appearing as linear struc-
tures, and sometimes as punctate staining, indicating pre-
sumed nerves in cross-section. Therefore, the following
parameters were used in order to exclude structures above
or below a certain size as being potentially non-neuronal
and to exclude inflammatory cells since monocytes and
macrophages have been reported to express TRPV1 [95].
In this context, for image analysis of nerves, the NIS-
Elements AR 3.0 Imaging software was set to count only
structures with length between 0.19-500 μm and width
0.19-2.5 μm. [Length is a derived feature appropriate for
elongated or thin structures. Length = (Perimeter + sqrt
(Perimeter2 - 16*Area))/4]; and Width is a derived feature
appropriate for elongated or thin structures. It is based on
the rod model and is calculated according to the following
formula: Width = Area/Length].
To meet the independent randomized sampling as-
sumption required for our statistical test(s), the following
measures were taken: blinding the reader to treatment
groups and picking a random starting position and pro-
ceeding clockwise with 6-10 non-overlapping images. As
12-20 fields are necessary to view the whole bladder
cross-section at 400X magnification, the sampling of 6-10
non-overlapping images represented half of the entire
bladder cross-section. The area occupied by cells stained
positively with td tomato or TRPV1 antibody was calcu-
lated as percent of the total area of the region of interest
(ROI), as indicated in the individual figure legend and the
results of 6-10 fields were averaged. This procedure was
repeated for all bladders used per treatment group and the
results are expressed as mean ± SEM of cross-sections.
The data were examined to determine if the distributions
were homoscedastic and Gaussian. As these conditions
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Student’s t test. An alpha of 0.05 was considered statisti-
cally significant. P-values were adjusted for multiple com-
parisons through a Bonferroni correction.
Surgical procedure to catheterize the urinary bladder
in mice
Mice included in the group for urodynamic evaluation of
the urinary bladder function (awake cystometry) under-
went the following survival surgical procedure to insert
bladder catheters. An animal was anesthetized with iso-
flurane (VEDCO, St. Joseph, MO), and a PTF catheter
with a blunted end (Catamount Research, St. Albans, VT)
was sutured in place at the bladder dome and tunneled
out the abdomen to the nape of the neck where it was
then inserted into the end of a 22-gauge angiocath iv cath-
eter. Upon determination of the optimal length, the PTF
catheter was affixed to the angiocath with super glue. The
angiocath was first tested with a gentle saline infusion to
reveal no leak at the bladder, and then capped and the ab-
domen was closed in layers. The angiocath was anchored
to the fascia and skin of the neck using two to three 3–0
Vicryl sutures. Animals were kept in individual cages to
avoid possible damage to the catheters by their cage
mates. Mice were allowed to recover from surgery for 4
days followed by cystometric evaluation of bladder func-
tion under normal conditions (baseline cystometry). After
initial urodynamic evaluation mice received 3 intravesical
instillations of VEGF as described above.
Surgical procedure for labeling urinary bladder
DRG neurons
Mice were anaesthetized with 2% isoflurane and held on a
warming pad inside a fume hood to minimize the investi-
gator`s exposure to the anesthetic. A midline laparotomy
was performed under sterile conditions to gain access to
the urinary bladder. Urinary bladder was exposed and Fast
Blue (Polysciences Inc., Warrington, PA, USA; 1.5% w/v in
water) was injected into the urinary bladder wall (detrusor
at 6 – 10 sites) using a Hamilton syringe with 26-gauge
needle. The total volume of dye injected into the bladder
was 20–25 μl. Adjacent pelvic organs were isolated with
gauze to soak up any spills and prevent the labeling of ad-
jacent structures during injections. Additionally, the nee-
dle was kept in place for 30 minutes after each injection.
Any leaked dye was removed with a cotton swab before
placing the organ into the pelvic cavity. Incisions were
sutured in layers under sterile conditions followed by sub-
cutaneous injection of buprenorphine (0.5 mg/kg). Ani-
mals were allowed to recover on a warm blanket until
they gained full consciousness and then were returned to
their cages. Mice started treatments with intravesical
VEGF (or PBS in the control group) 10 days after labeling
of bladder sensory neurons.Urodynamic evaluation of bladder function
Conscious mice were placed in cystometry cages (16 cm
width, 12 cm height, and 24 cm length) without any re-
straint and allowed to acclimate for 30 min. The tip of the
exteriorized bladder catheter located at the base of the
mouse neck was connected to a pressure transducer and
an infusion pump of the cystometry station (Small Animal
Laboratory Cystometry, Catamount Research and Devel-
opment, St. Albans, VT) using a T-shaped valve. Room
temperature saline solution (0.9% NaCl) was infused into
the bladder at a rate of 10 μl/min. Voided urine was col-
lected in the tray connected to a force displacement trans-
ducer integrated into the data acquisition system. Each
animal was observed for up to six-eight voiding cycles.
Urodynamic values were recorded continuously using data
acquisition software (Small Animal Laboratory Cystometry,
Catamount Research and Development). The following
cystometric parameters were recorded and analyzed in this
study: bladder capacity, pressure at the start of micturition,
micturition rate, continuous intravesicular pressure, inter-
micturition interval, and the number of non-micturition
contractions. Non-micturition contractions were defined as
increased values in detrusor pressure from the baseline that
had amplitudes of at least a third of maximal pressure at
the start of micturition. Each animal underwent baseline
cystometric evaluation followed by intravesical instillations
of VEGF. The second cystometric assessment was done
after two VEGF instillations (1 week after the first dose)
and the third cystometry was performed 3 days after
completion of all three VEGF treatments at 2 weeks after
the baseline measurement (day 0), Table 1.
Cystometric parameters were uploaded from the acqui-
sition software into analysis software (SOF-552 Cystome-
try Data Analysis, Version 1.4, Catamount Research and
Development Inc., St. Albans, Vermont). Maximum pres-
sure at micturition, bladder capacity, micturition volume,
number of non-micturition contractions, intermicturition
interval and micturition rate indices were calculated. All
data are expressed as the mean ± standard error of the
mean (S.E.M). The results were statistically analyzed using
one-way repeated measures ANOVA between baseline
and 2 urodynamic assessments followed by Bonferroni`s
post test, as appropriate (Systat Software Inc., San Jose,
CA). A difference in values between the baseline and treat-
ments was considered statistically significant at p≤0.05.
Isolation of bladder DRG neurons for
patch-clamp experiments
Animals were euthanized by overdose of sodium pento-
barbital (130 mg/kg) 2 weeks after the beginning of VEGF
treatments. Dorsal root ganglia were dissected and
removed bilaterally at L6-S2 levels. The ganglia were trea-
ted with collagenase (Worthington, type 2, Biochemical
Corp., Lakewood, NJ, USA) in F-12 medium (Invitrogen,
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O2 and 5% CO2 at 37° C. Isolated ganglia were then rinsed
in phosphate-buffered saline (PBS) and incubated for
15 min in the presence of trypsin (Sigma, St Louis, MO,
USA; 1 mg/ml) at room temperature. The enzymatic reac-
tion was terminated in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 10% of fetal bovine serum
(FBS). Single neurons were obtained by gentle trituration
using fire-polished Pasteur pipettes in DMEM with tryp-
sin inhibitor (Sigma; 2 mg/ml) and deoxyribonuclease
(Sigma; DNase 1 mg/ml). The cell suspension was centri-
fuged for 10 min at 700 rpm (4° C), and supernatant was
discarded. The pellet, containing sensory neurons, was
resuspended in 2 ml of DMEM containing 10% FBS. Neu-
rons were plated on poly-L-ornithine coated 35 mm Petri
dishes. Isolated cells were maintained overnight in an in-
cubator at 37° C with 95% O2/5% CO2 and were used for
electrophysiological experiments within 24 hours.Electrophysiological recordings of voltage gated Na+
currents from bladder dorsal root ganglion neurons
Bladder labeled neurons were identified with an inverted
fluorescent microscope (Ti E2000–5, Nikon containing a
specific filter for Fast Blue (UV-2A, Nikon). Only neurons
exhibiting bright blue fluorescence (Fast Blue labeled)
were used for Na+ current recordings using the whole-cell
patch clamp technique. For voltage clamp experiments
the external solution contained (in mM): NaCl 45, TEA
Chloride 30, Choline Chloride 60, KCl 5.4, MgCl2 1, CaCl2
1, HEPES 5, D-glucose 5.5, adjusted with NaOH to pH
7.4. Pipette solution for these experiments consisted of (in
mM): L-aspartic acid 100, CsCl 30, MgCl2 2, Na-ATP 5,
EGTA 5, HEPES 5 adjusted with CsOH to pH 7.2. CdCl
(100 μM) was added to the external solution in order to
block voltage gated calcium currents. Freshly made
Amphotericin B (0.24 mg/ml, ACROS, NJ, USA) was
added to the pipette solution for perforated whole cell
recordings. Microelectrodes were fabricated from borosili-
cate capillary glass (Sutter instruments, Novato, CA) and
had resistances of 2–5 MΩ when filled with internal
solution. Recordings commenced 5 min after the estab-
lishment of whole cell access. Series resistance was com-
pensated ≥80–85%, and the calculated junction potential
was around 5 mV. Cells were excluded from analysis if un-
compensated series resistance resulted in a maximum
voltage error >5 mV or if the seal or access resistance were
unstable. Recordings and analysis of kinetic parameters of
voltage gated Na+ channels were performed using previ-
ously established protocols [9].
pCLAMP software (Axon Instruments, CA) was used
for data acquisition and analysis. All data are expressed
as means ± SEM. Statistical significance between the
groups was assessed by one-way ANOVA followed byBonferroni`s test. Data with p≤0.05 were considered sta-
tistically significant.Assessment of visceral sensitivity using
von Frey filaments
Mice were tested before and after intravesical instillations
of VEGF. Irritation and/or inflammation in the pelvic vis-
cera are associated with enhanced abdominal sensitivity
due to convergence of visceral and somatic inputs on the
second order neurons in the dorsal horn of the spinal cord
[21]. This phenomenon is known as viscerosomatic (called
hyperalgesia) and is measured by using mechanical stimu-
lation with von Frey filaments on the lower abdominal/
pelvic area. Mice were tested in individual Plexiglas cham-
bers (6 x 10 x 12 cm) with a stainless steel wire grid floor
(mouse acclimation period was 30 min before testing).
Frequency of withdrawal responses was tested using five
individual fibers with forces of 0.04, 0.16, 0.4, 1, and 4 g
(Stoelting). Each filament was applied for 1–2 s with an
interstimulus interval of 5 s for a total of 10 times, and the
hairs were tested in ascending order of force. Stimulation
was confined to the lower abdominal area in the general
vicinity of the bladder, and care was taken to stimulate dif-
ferent areas within this region to avoid desensitization or
"wind up" effects. Three types of behavior were considered
as positive responses to filament stimulation: 1) sharp re-
traction of the abdomen, 2) immediate licking or scratch-
ing of the area of filament stimulation, or 3) jumping as
previously described [96].
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